Yamamoto A, Shimizu E, Takeuchi E, Houchi H, Doi H, Bando H, Ogura T, Sone S
Third Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, Japan.
Oncology. 1999;56(2):129-33. doi: 10.1159/000011953.
To clarify the host immune response and explore a new serological marker of lung cancer, we examined serum c-Myc antigens and auto-antibodies against c-Myc in 68 lung cancer patients and 30 healthy volunteers using bacterially synthesized glutathione S-transferase c-Myc fusion proteins and immunoblotting. The detection rate of anti-c-Myc antibodies was 13.2% (9/68) in lung cancer patients and 3.3% (1/30) in healthy volunteers. These anti-c-Myc antibodies were directed toward exon 2 alone (4/68), exon 3 alone (1/68), and both exon 2 and exon 3 (4/68) of c-Myc. Circulating c-Myc antigen was not detected in any individuals with lung cancer and normal controls. Age, sex, performance status, histology, stage, smoking history, and prior treatment of the patients with and without anti-c-Myc antibodies were not significantly different. The low incidence of anti-c-Myc antibodies and c-Myc antigens in peripheral blood suggests that these examinations are not useful in the serological diagnosis of lung cancer.
为了阐明宿主免疫反应并探索肺癌的一种新的血清学标志物，我们使用细菌合成的谷胱甘肽S-转移酶c-Myc融合蛋白和免疫印迹法，检测了68例肺癌患者和30名健康志愿者血清中的c-Myc抗原及抗c-Myc自身抗体。肺癌患者中抗c-Myc抗体的检出率为13.2%（9/68），健康志愿者中为3.3%（1/30）。这些抗c-Myc抗体仅针对c-Myc的外显子2（4/68）、仅外显子3（1/68）以及外显子2和外显子3两者（4/68）。在任何肺癌患者和正常对照个体中均未检测到循环c-Myc抗原。有和没有抗c-Myc抗体的患者在年龄、性别、体能状态、组织学类型、分期、吸烟史及既往治疗方面无显著差异。外周血中抗c-Myc抗体和c-Myc抗原的低发生率表明，这些检测在肺癌的血清学诊断中并无用处。
